Alector
Alector's revenue fell 79.1% to $21 million in fiscal 2025. Its operating margin was −741.3%, down from −144.2% a year earlier. Free cash flow was −$184 million. The diluted share count rose 6.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Alector does
Alector is a clinical-stage biotechnology company that develops medicines for brain diseases such as Alzheimer's and Parkinson's disease. It has no approved products and no product sales. Its work focuses on treatments that remove harmful proteins, replace missing proteins or restore normal cell function.
Its most advanced candidate, nivisnebart, is an antibody designed to raise levels of a protein called progranulin in the brain. Alector and GlaxoSmithKline are developing it together, and a Phase 2 study in early Alzheimer's disease has finished enrolling. Under that 2021 agreement, Alector funds and shares development costs up to $140.5 million for the initial Phase 2 trial.
Alector's own programs are earlier, in preclinical work. They include an antibody against amyloid beta for Alzheimer's, an enzyme therapy for Parkinson's disease and small interfering RNA drugs targeting tau and other proteins. Many use its Alector Brain Carrier, a technology designed to carry drugs across the blood-brain barrier. It may seek partners for its programs.
Its biggest risks, as it describes them
- None of its candidates is approved, and its trials may fail or be delayed.
- It has no product sales and depends on funding and on its collaboration with GSK.
- Its blood-brain barrier technology may not work well enough in people.
- It may need to raise more money, which could dilute owners.
Income statement
Alector lost money in fiscal 2025: a net loss of $143 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 735 | 713 | 549 | 413 | 256 |
| Debt incl. finance leases | — | — | 0 | 10 | 10 |
| Net debt (negative means net cash) | — | — | −549 | −403 | −246 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | 0.0x | 0.1x | 0.3x |
| Interest coverage | — | — | — | — | −182.5x |
| Current ratio | 5.4x | 7.7x | 3.2x | 3.4x | 3.8x |
| Quick ratio | 5.4x | 7.7x | 3.2x | 3.4x | 3.8x |
Cash flow
Projections
Project Alector's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Alector shares on the open market, and 4 insiders sold $1.0 million, $72,899 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 4, 2026 | Grace Wong-SaradPrincipal Accounting Officer | Sold plan | 3,625 | $2.51 | $9,099 | Form 4 |
| Sep 3, 2026 | Arnon RosenthalChief Executive Officer, Director | Sold | 72,606 | $2.66 | $193,132 | Form 4 |
| Sep 3, 2026 | Neil Lindsay BerkleyCFO & Chief Business Officer | Sold | 29,251 | $2.66 | $77,808 | Form 4 |
| Sep 3, 2026 | Grace Wong-SaradPrincipal Accounting Officer | Sold plan | 5,165 | $2.67 | $13,791 | Form 4 |
| Sep 2, 2026 | Grace Wong-SaradPrincipal Accounting Officer | Sold plan | 656 | $2.75 | $1,804 | Form 4 |
| Jun 3, 2026 | Grace Wong-SaradPrincipal Accounting Officer | Sold plan | 3,475 | $1.88 | $6,533 | Form 4 |
| Jun 2, 2026 | Arnon RosenthalChief Executive Officer, Director | Sold | 87,216 | $1.97 | $171,816 | Form 4 |
| Jun 2, 2026 | Neil Lindsay BerkleyCFO & Chief Business Officer | Sold | 19,360 | $1.97 | $38,139 | Form 4 |
| Jun 2, 2026 | Grace Wong-SaradPrincipal Accounting Officer | Sold plan | 5,709 | $1.97 | $11,247 | Form 4 |
| Apr 16, 2026 | Grace Wong-SaradPrincipal Accounting Officer | Sold plan | 1,820 | $2.65 | $4,823 | Form 4 |
| Mar 10, 2026 | Grace Wong-SaradPrincipal Accounting Officer | Sold plan | 1,000 | $2.65 | $2,650 | Form 4 |
| Mar 3, 2026 | Grace Wong-SaradPrincipal Accounting Officer | Sold plan | 3,367 | $2.08 | $7,003 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | 2 of 8 | 1 of 8 |
| Rule of 40 | −219.4% | −226.3% | −953.7% |
| Altman Z'' | −0.98 | −3.26 | −9.85 |
| Accruals ratio | 7.6% | 20.3% | 10.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Fail | Fail | Fail |
| Debt fell relative to assets | — | Fail | Fail |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | — | 2 of 8 | 1 of 8 |
Compare
Put Alector side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Alector | FY25 | −79.1% | −741.3% | −874.7% | — | — | 1 | |
| LENZ Therapeutics | FY25 | — | −477.5% | −366.7% | — | — | — | Compare |
| Metagenomi Therapeutics | FY25 | −51.8% | −380.9% | −354.9% | — | — | — | Compare |
| Entrada Therapeutics | FY25 | −87.9% | −621.1% | −509.6% | — | — | — | Compare |
| MediWound | FY25 | −16.1% | −149.0% | −127.5% | — | — | — | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 4 | 28 | 21 | 21 | 207 | 134 | 97 | 101 | 21 |
| Revenue growth | — | 641.0% | −23.3% | −0.6% | 881.5% | −35.5% | −27.3% | 3.6% | −79.1% |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Research and development | 30 | 73 | 100 | 157 | 189 | 210 | 192 | 186 | 123 |
| Operating income | −33 | −57 | −114 | −195 | −37 | −138 | −152 | −145 | −156 |
| Net income | −32 | −52 | −105 | −190 | −36 | −133 | −130 | −119 | −143 |
| Diluted EPS (US$) | −3.55 | −4.62 | −1.71 | −2.45 | −0.45 | −1.62 | −1.56 | −1.23 | −1.39 |
| Diluted shares (millions) | 9 | 11 | 62 | 78 | 80 | 82 | 84 | 97 | 103 |
| Cash flow | |||||||||
| Cash from operations | −18 | 128 | −99 | −167 | 299 | −20 | −184 | −230 | −184 |
| Capital expenditure | 1 | 2 | 15 | 5 | 3 | 4 | 2 | 1 | 0 |
| Free cash flow | −19 | 126 | −115 | −172 | 295 | −24 | −187 | −231 | −184 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 5 | 7 | 16 | 30 | 41 | 46 | 43 | 40 | 27 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 32 | 290 | 353 | 413 | 735 | 713 | 549 | 413 | 256 |
| Debt incl. finance leases | — | — | — | — | — | — | 0 | 10 | 10 |
| Total assets | — | 308 | 422 | 488 | 815 | 788 | 622 | 468 | 293 |
| Total liabilities | — | 195 | 227 | 221 | 514 | 573 | 488 | 342 | 263 |
| Shareholders' equity | −52 | −97 | 195 | 268 | 301 | 214 | 134 | 127 | 31 |
| Margins and ratios | |||||||||
| Gross margin | — | — | — | — | — | — | — | — | — |
| Operating margin | −874.9% | −207.0% | −539.2% | −925.1% | −18.0% | −103.2% | −156.3% | −144.2% | −741.3% |
| Net margin | −869.6% | −188.8% | −496.6% | −901.6% | −17.5% | −99.8% | −134.3% | −118.4% | −679.2% |
| Free cash flow margin | −497.2% | 453.7% | −540.0% | −814.1% | 142.6% | −18.3% | −192.1% | −229.9% | −874.7% |
| Rule of 40 (growth + FCF margin) | — | 1,094.8% | −563.3% | −814.7% | 1,024.1% | −53.8% | −219.4% | −226.3% | −953.7% |
| Return on capital | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | −216.5% | −82.3% | −12.8% | −51.8% | −74.8% | −91.2% | −181.6% |
| Return on assets | — | — | −28.9% | −41.8% | −5.6% | −16.6% | −18.5% | −21.8% | −37.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |